市場調查報告書
商品編碼
1545622
全球生物電子醫學市場:依類型、產品、應用、最終用戶和地區預測(~2030年)Global Bioelectric Medicine Market Research Report Information by Type, by Product, By Application, By End User, By Region - Forecast till 2030 |
在預測期內,生物電子醫學市場規模預計將以 6.53%的年複合成長率成長。
生物電子醫療產業是由全球慢性病盛行率上升以及參與營運商不斷增加的策略性舉措所推動的。根據世界衛生組織統計,2019年類風濕性關節炎影響了1,800萬人,其中70%是女性,其中55%年齡在55歲以上。此外,英國克隆氏症和結腸炎估計,到2022年,英國每 123 人中就有 1 人患有克隆氏症或潰瘍性結腸炎。儘管有人擔心生物電醫療設備的高成本將阻礙市場成長,但臨床試驗的擴大和新進入公司的投資增加預計將為該行業提供有利的前景。
區域洞察
北美市場在2022年佔據最大市場佔有率,為 38.01%,預計到2030年將成長至約 160億美元,預測期內年複合成長率為 4.71%。預計亞太地區在預測期內也將呈現最高成長率,年複合成長率為 8.99%。
北美生物電子醫療市場的前景仍然光明,預計將持續擴張。對醫療基礎設施的投資和對現代醫療解決方案意識的提高預計將進一步推動市場成長。現有企業和新進業者都準備好利用技術進步並抓住這些機會來滿足對更好手術結果日益成長的需求。
由於技術進步、醫療成本上升、慢性病盛行率上升,歐洲市場佔據第二大市場。此外,德國生物電子醫療市場擁有最大的市場佔有率,法國生物電子醫療市場預計將成為歐洲成長最快的市場。
由於患者人數眾多、慢性病盛行率不斷上升以及有利的監管政策,預計亞太市場將在2023年至2032年期間發展最快。此外,各大公司不斷向該地區擴張,加速了該地區市場的成長。預計中國將佔最大佔有率,印度預計將成為成長最快的市場。
本報告調查了全球生物電醫學市場,提供了市場定義和概述,市場成長的各種影響因素分析,市場規模推移和預測,各種區分、地區的細分,競爭環境、主要企業概況等彙整資料。
Global Bioelectric Medicine Market Research Report Information by Type (Implantable Electroceutical Devices and Non-invasive Electroceutical Devices), by Product (Implantable Cardioverter Defibrillators, Cardiac Pacemakers, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Transcutaneous Electrical Nerve Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, And Others), By Application (Arrhythmia, Pain Management, Sensorineural Hearing Loss, Epilepsy, And Others), By End User (Hospitals & Clinics, ASCs, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030
The Bioelectric Medicine Market is expected to expand at a compound annual growth rate (CAGR) of 6.53% over the projected period. The Bioelectric Medicine industry is being driven by rising prevalence of chronic diseases around the world, as well as increased strategic initiatives by industry participants. According to the World Health Organization, 18 million individuals suffered from rheumatoid arthritis in 2019, with 70% of them being women and 55% being over the age of 55. Furthermore, Crohn's & Colitis UK estimated that one in every 123 persons in the UK will have Crohn's disease or ulcerative colitis by 2022. However, the high cost of bioelectric medical devices is projected to hinder global market growth. Nonetheless, expanding clinical trials for bioelectric medicine and increased investment in bioelectric medicine by market participants are expected to generate profitable prospects for the industry.
The increasing prevalence of chronic diseases around the world is considerably contributing to the expansion of bioelectric medicine. Chronic diseases, including chronic pain conditions, neurological disorders, inflammatory diseases, and metabolic disorders, place a significant strain on healthcare systems and have a negative influence on patients' quality of life. Traditional treatment approaches, such as medicines and surgery, may have limited success or carry concerns of side effects for some people. The increasing prevalence of disorders, together with bioelectric medicine's prospective applicability in these circumstances, is driving up demand for bioelectric medicine products. For example, deep brain stimulation (DBS) has been proven to be effective in treating Parkinson's disease symptoms by regulating aberrant neural activity. Similarly, neuromodulation devices such as vagus nerve stimulation (VNS) have showed efficacy in lowering seizure frequency in epilepsy patients. Furthermore, in February 2024, the World Health Organization stated that approximately 50 million individuals worldwide suffer from epilepsy, with nearly 80% living in low- and middle-income nations.
Market Segment insights
Product-wise, the global bioelectric medicine segment includes implantable cardioverter defibrillators, cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators, sacral nerve stimulators, vagus nerve stimulators, and others.
The bioelectric medicine market is divided into two types: implanted electroceutical devices and noninvasive electroceutical devices.
The Bioelectric Medicine Market has been categorized by application, including arrhythmia, pain management, sensorineural hearing loss, Parkinson's disease, tremor, depression, epilepsy, urine and fecal incontinence, among others.
The market is divided into three segments based on the end user: hospitals, research institutes, and others.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America's bioelectric medicine market held the greatest market share of 38.01% in 2022 and is expected to reach roughly USD 16.00 billion by 2030, growing at a 4.71% CAGR during the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 8.99% over the forecast period.
The future for the North American bioelectric medicine market remains positive, with continued expansion expected. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.
Europe's bioelectric medicine market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increase in the prevalence of chronic conditions. Furthermore, the Germany bioelectric medicine market is expected to have the greatest market share, with France's bioelectric medicine market forecast to be the fastest expanding market in Europe.
The Asia-Pacific bioelectric medicine market is predicted to develop the fastest between 2023 and 2032 due to its large patient population, increased prevalence of chronic diseases, and favorable regulatory policies. Furthermore, prominent market companies are constantly expanding into this region, accelerating regional market growth. Furthermore, China's bioelectric medicine market held the greatest market share, while India's bioelectric medicine market is expected to be the fastest expanding market in the Asia-Pacific region.
Abbott (US), Boston Scientific Corporation (US), Bortnick (Germany), Aleva Neurotherapeutics (Switzerland), Cochlear Ltd. (Australia), LivaNova PLC (UK), Medtronic (Ireland), Charco Neurotech (UK), ElectroCore, Inc. (US), and Nevro Corp (US) are some of the key companies in the Bioelectric Medicine market.